NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

ISCA2-Related Mitochondrial Disorder

Synonym: Multiple Mitochondrial Dysfunction Syndrome 4

, MD and , PhD.

Author Information

Initial Posting: .

Summary

Clinical characteristics.

Infants with ISCA2-related mitochondrial disorder (IRMD) typically attain normal development in the first months of life. At age three to seven months, affected individuals usually present with a triad of neurodevelopmental regression, nystagmus with optic atrophy, and diffuse white matter disease. As the disease progresses, global psychomotor regression continues at a variable pace and seizures may develop. Affected children become vegetative within one to two years. During their vegetative state, which may persist for years, affected individuals are prone to recurrent chest infections that may require ventilator support. Most affected individuals die during early childhood.

Diagnosis/testing.

The diagnosis of ISCA2-related mitochondrial disorder is established in a proband by the identification of biallelic pathogenic variants in ISCA2 on molecular genetic testing.

Management.

Treatment of manifestations: Treatment is primarily supportive and may require input from a geneticist, neurologist, dietician, and developmental specialist. A feeding tube (nasogastric or gastrostomy) is typically required. Standard treatment for epilepsy. Recurrent chest infections may require ventilator support in addition to antimicrobial therapy. Referral to early intervention services is recommended. For muscle tone abnormalities including hypertonia, baclofen and/or Botox® may be considered.

Prevention of secondary complications: Constipation may become problematic and may require ensuring adequate hydration and/or treatment with stool softeners or laxatives.

Surveillance: Periodic evaluation of swallowing function is suggested.

Genetic counseling.

ISCA2-related mitochondrial disorder is inherited in an autosomal recessive manner. At conception, each sib of an affected individual with IRMD has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the ISCA2 pathogenic variants in the family are known.

Diagnosis

ISCA2-related mitochondrial disorder (IRMD) is a severe neurodegenerative condition; consensus clinical diagnostic criteria have not been published.

Suggestive Findings

IRMD should be suspected in infants with the following neurologic, ophthalmologic, head imaging, and supportive laboratory findings.

Neurologic findings

  • Progressive loss of developmental milestones, typically beginning between ages three and seven months
  • Spasticity
  • Impaired speech

Ophthalmologic features

  • Optic atrophy
  • Nystagmus

Head MRI findings

  • Diffuse bilateral symmetric signal abnormality in cerebral white matter
  • In some cases, signal abnormalities in the corpus callosum, internal capsule, midbrain, middle cerebellar peduncles, and cervical spinal cord

Supportive laboratory findings

Note: (1) Respiratory chain enzyme analysis is not required to make the diagnosis. (2) More invasive testing that requires a skin or muscle biopsy sample may be bypassed in favor of molecular genetic testing on a peripheral blood sample (see Establishing the Diagnosis).

Establishing the Diagnosis

The diagnosis of ISCA2-related mitochondrial disorder is established in a proband by identification of biallelic pathogenic variants in ISCA2 on molecular genetic testing (see Table 1)

Molecular genetic testing approaches can include use of a multigene panel, more comprehensive genomic testing, and (rarely) single-gene testing.

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Because the phenotype of IRMD is similar to a wide range of neurodegenerative conditions, genomic testing is typically pursued first.

Recommended Genomic Testing

A multigene panel that includes ISCA2 and other genes of interest (see Differential Diagnosis) may be considered first. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

More comprehensive genomic testing (when available) including exome sequencing, mitochondrial sequencing, and genome sequencing may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).

For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Further Testing to Consider

Single-gene testing may (rarely) be considered if the clinical features are highly suggestive of IRMD. Only one pathogenic variant has been identified, and it is likely a founder variant [Al-Hassnan et al 2015]. Targeted analysis for this variant may be considered in consanguineous families from Saudi Arabia.

Table 1.

Molecular Genetic Testing Used in ISCA2-Related Mitochondrial Disorder

Gene 1Test MethodProportion of Probands with Pathogenic Variants 2 Detectable by This Method
ISCA2Targeted testing for c.229G>A pathogenic variant 318/19 4
Sequence analysis 5~100% 3
Gene-targeted deletion/duplication analysis 6Unknown 7
1.
2.

See Molecular Genetics for information on allelic variants detected in this gene.

3.

One pathogenic founder variant has been reported [Al-Hassnan et al 2015]. Compound heterozygosity for two variants (c.295delT and c.334A>G) has been reported in a single affected individual [Toldo et al 2018], whose features differed slightly from the originally described cohort of individuals, who were all homozygous for the founder variant.

4.
5.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

6.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

7.

No data on detection rate of gene-targeted deletion/duplication analysis are available.

Clinical Characteristics

Clinical Description

Only 20 individuals with this condition have been reported [Alazami et al 2015, Al-Hassnan et al 2015, Alaimo et al 2018, Alfadhel et al 2018, Toldo et al 2018]. Infants with IRMD attain normal development in the first months of life. At age three to seven months 18 out of 18 individuals reported have experienced progressive loss of milestones with irritability, inattention, and inability to perform previously acquired motor skills. Nystagmus on presentation has been reported in eight of 12 individuals assessed. Clinical evaluation reveals central hypotonia that progresses to limb spasticity and hyperreflexia (18/18). Optic atrophy with progressive loss of vision has been observed in 18 of 18 affected individuals evaluated. As the disease progresses, global psychomotor regression continues at a variable pace and seizures (3/10) may develop. Seizures are generalized tonic-clonic and are responsive to anticonvulsant treatment [Alfadhel et al 2018]. Affected children become vegetative within one to two years. During their vegetative state, which may persist for years, affected individuals are prone to recurrent chest infections that may require ventilator support. Most affected individuals die during early childhood. As the disease is severe with no known cure, continuing to provide supportive care, including invasive ventilation, must be seriously reviewed. Progressive multiorgan (liver, kidney, heart) failure has not been observed in this condition.

Dysmorphic features (low-set ears, broad nasal bridge, short fourth metacarpals, cutaneous toe syndactyly) have been rarely observed (2/18) [Alaimo et al 2018].

A rapidly progressive severe course with neonatal leukoencephalopathy and death at age three months was reported in a single affected individual who had biallelic novel (non-founder) pathogenic ISCA2 variants [Toldo et al 2018].

Since so few cases have been identified, understanding of the clinical phenotypic spectrum and natural history continues to evolve.

Neuroimaging with brain MRI typically demonstrates extensive diffuse bilateral symmetric signal abnormality in cerebral periventricular white matter, most often sparing the U-fibers. These changes are hyperintense on T2-weighted images. Signal abnormalities can also be seen in other areas of the brain (see Suggestive Findings), although the basal ganglia are usually spared [Al-Hassnan et al 2015]. High lactate, glycine, and glutamine/glutamate peaks may also be seen in brain MR spectroscopy [Alaimo et al 2018, Alfadhel et al 2018, Toldo et al 2018].

Muscle biopsy from one affected individual has been analyzed; it demonstrated minimal histologic changes [Al-Hassnan et al 2015]. The hematoxylin- and eosin-stained frozen sections of the skeletal muscle showed mild to moderate variation in myofiber size with moderately to severely atrophic fibers in a random distribution. There were no significant myopathic features, such as fiber degeneration, regeneration, or hypertrophy. Ragged red fibers were not observed. Ultrastructural examination of a representative preserved area showed normal myofibrillar organization and cellular organelles with only a few small accumulations of structurally normal mitochondria.

Genotype-Phenotype Correlations

One affected infant who had diffuse hypotonia, a rapidly progressive course, and no optic atrophy was found to have biallelic novel (non-founder) pathogenic ISCA2 variants (see Table 1, footnote 3) [Toldo et al 2018]. It is unclear whether the atypical presentation was a result of the novel variants or an instance of the clinical variability often seen among individuals with the same condition.

Prevalence

The prevalence of IRMD is unknown. Twenty affected individuals from 18 families have been reported in the literature [Alazami et al 2015, Al-Hassnan et al 2015, Alaimo et al 2018, Alfadhel et al 2018]. Most (19/20) of the affected individuals reported are from Saudi Arabia, which may suggest a higher prevalence of the disorder in Arabs. A single affected individual from Italy has been reported [Toldo et al 2018].

Differential Diagnosis

The differential diagnosis of neurologic regression with white matter disease in infancy is extensive. Diagnostic algorithms for genetic leukodystrophy disorders have been published (see Leukodystrophy Overview). In ISCA2-related mitochondrial disorder (IRMD), the constellation of extensive periventricular leukodystrophy, optic atrophy, and biochemical and/or histopathologic evidence of mitochondrial involvement is suggestive of the disorder but can also be seen in other conditions.

Table 2.

Disorders to Consider in the Differential Diagnosis of ISCA2-Related Mitochondrial Disorder (IRMD)

DisorderGene(s)MOIClinical Features of This Disorder
Overlapping w/IRMDDistinguishing from IRMD
Multiple mitochondrial dysfunctions syndrome 1NFU1AR
  • Feeding difficulties
  • Muscle weakness
  • Decreasing responsiveness
  • Neurologic regression
  • White matter lesions on brain MRI
  • Lactic acidosis
  • Decreased activity of mt respiratory complexes
  • Pulmonary hypertension
  • Obstructive vasculopathy
  • Spongiform degeneration & white matter necrosis
  • Onset soon after birth
Multiple mitochondrial dysfunctions syndrome 2BOLA3AR
  • Optic atrophy
  • Visual impairment
  • Spasticity
  • Leukodystrophy
  • Spinal cord lesions
  • Lactic acidosis
  • Onset in infancy
  • Decreased activity of mt respiratory complexes
  • Cardiomyopathy
  • Hepatomegaly
  • Extrapyramidal signs
  • Ataxia
  • Myoclonus
Multiple mitochondrial dysfunctions syndrome 3IBA57AR
  • White matter abnormalities
  • Lactic acidosis
  • Decreased activity of mt respiratory complexes
  • Onset in utero
  • Intrauterine growth restriction
  • Microcephaly
  • Dysmorphic features (retrognathia, high-arched palate, widely spaced nipples)
  • Arthrogryposis
  • Severe hypotonia
  • Polymicrogyria
  • Hypoplasia of the corpus callosum
  • Hypoplasia of the medulla oblongata
ISCA1-related disorderISCA1AR
  • Neurologic regression
  • White matter abnormalities
  • Lactic acidosis
Abnormalities of cortical migration
Metachromatic leukodystrophyARSA or PSAPAR
  • Neurologic regression
  • Leukodystrophy
  • Spasticity
  • Optic atrophy
Increased urinary sulfatide excretion
Krabbe diseaseGALCAR
  • Neurologic regression
  • Leukodystrophy
  • Spasticity
  • Optic atrophy
Pattern of MRI findings, including involvement of thalami & caudate
Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevationDARS2AR
  • Neurologic regression
  • Elevation of lactate in serum & MR spectroscopy
Pattern of MRI findings
Childhood ataxia with central nervous system hypomyelination/vanishing white matterEIF2B1
EIF2B2
EIF2B3
EIF2B4
EIF2B5
AR
  • Neurologic regression
  • Leukodystrophy
  • Spasticity
  • Optic atrophy
  • Unsteady gait
  • Pattern of MRI findings
  • Ovarian dysgenesis in females
Canavan diseaseASPAAR
  • Neurologic regression
  • Leukodystrophy
  • Optic atrophy
  • Macrocephaly
  • Pattern of MRI findings
  • Increased N-acetyl-L-aspartate in urine
Alexander diseaseGFAPAD
  • Neurologic regression
  • Leukodystrophy
  • Spasticity
  • Optic atrophy
  • Macrocephaly
  • Pattern of MRI findings
Leigh syndromeHeterogeneousAR
XL
mt
  • Neurologic regression
  • Elevation of lactate in serum & MR spectroscopy
  • Hypertrophic cardiomyopathy
  • Hypertrichosis
  • Renal tubulopathy
  • Liver involvement
  • Bilateral symmetric T2-weighted hyperintensities in the basal ganglia and/or brain stem on MRI
  • Basal ganglia involvement

Other leukodystrophies and lysosomal storage diseases. Other progressive degenerative disorders that manifest in infancy can mimic IRMD. In the presence of leukodystrophy, other conditions to consider include Pelizaeus-Merzbacher disease and GM2 gangliosidoses (Tay-Sachs disease [hexosaminidase A deficiency] and Sandhoff disease).

See Multiple Mitochondrial Dysfunctions Syndrome: OMIM Phenotypic Series to view genes associated with this phenotype in OMIM.

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with ISCA2-related mitochondrial disorder (IRMD), the following evaluations are recommended if they have not already been completed:

  • Neurologic evaluation to assess for tone and spasticity
  • Ophthalmologic examination to assess for optic atrophy
  • Brain MRI and MRS
  • Assessment of feeding problems, with consideration of a swallowing study
  • Assessment of nutritional status by monitoring growth parameters and serum chemistries, such as albumin and total protein
  • Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

The mainstay of treatment is supportive and is best provided by a multidisciplinary team including a geneticist, neurologist, and dietician.

Feeding via nasogastric tube or gastrostomy will be required in most cases.

Standard treatment for epilepsy is indicated for those who have seizures.

Recurrent chest infections may require ventilator support in addition to antimicrobial therapy.

Global Developmental Delay / Intellectual Disability Educational Issues

The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.

Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy. In the United States, early intervention is a federally funded program available in all states.

Ages 3-5 years. In the United States, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed.

All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:

  • Private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
  • In the United States:
    • Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
    • Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.

Gross Motor Dysfunction

Physical therapy is recommended to maximize mobility.

Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).

Prevention of Secondary Complications

With the progression of the disease, constipation can be a problem. Adequate hydration, stool softeners, and laxatives may help in avoiding severe constipation.

Surveillance

Periodic evaluation of swallowing function is suggested. Abnormal swallowing may prompt consideration of placement of a feeding tube.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and www.ClinicalTrialsRegister.eu in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

ISCA2-related mitochondrial disorder is inherited in an autosomal recessive manner.

Parents of a proband

  • The parents of an affected child are obligate heterozygotes (i.e., carriers of one ISCA2 pathogenic variant).
  • Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Sibs of a proband

  • At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
  • Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

Offspring of a proband. Individuals with ISCA2-related mitochondrial disorder are not known to reproduce.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of an ISCA2 pathogenic variant.

Carrier (Heterozygote) Detection

Carrier testing for at-risk relatives requires prior identification of the ISCA2 pathogenic variants in the family.

Related Genetic Counseling Issues

Family planning

  • The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Diagnosis

Once the ISCA2 pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • Australian Mitochondrial Disease Foundation (AMDF)
    Suite 4, Level 6, 9-13 Young Street
    Sydney
    Australia
    Phone: 1-300-977-180
    Fax: 02-9999-3474
    Email: info@amdf.org.au
  • United Mitochondrial Disease Foundation (UMDF)
    8085 Saltsburg Road
    Suite 201
    Pittsburg PA 15239
    Phone: 888-317-8633 (toll-free); 412-793-8077
    Fax: 412-793-6477
    Email: info@umdf.org
  • Mitochondrial Disease Registry and Tissue Bank
    Massachusetts General Hospital
    185 Cambridge Street
    Simches Research Building 5-238
    Boston MA 02114
    Phone: 617-726-5718
    Fax: 617-724-9620
    Email: nslate@partners.org
  • RDCRN Patient Contact Registry: North American Mitochondrial Disease Consortium

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

ISCA2-Related Mitochondrial Disorder: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

Table B.

OMIM Entries for ISCA2-Related Mitochondrial Disorder (View All in OMIM)

615317IRON-SULFUR CLUSTER ASSEMBLY 2, S. CEREVISIAE, HOMOLOG OF; ISCA2
616370MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 4; MMDS4

Gene structure. The longest transcript of ISCA2, NM_194279.3, has four exons. For a detailed summary of gene, transcript, and protein information, see Table A, Gene.

Pathogenic variants. One pathogenic founder variant has been reported to date [Alazami et al 2015, Al-Hassnan et al 2015, Alaimo et al 2018, Alfadhel et al 2018]. Toldo et al [2018] reported a single affected individual who was a compound heterozygote for novel ISCA2 variants (Table 3).

Table 3.

ISCA2 Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide ChangePredicted Protein ChangeReference Sequences
c.229G>Ap.Gly77SerNM_194279​.3
NP_919255​.2
c.295delT 1p.Phe99LeufsTer18
c.334A>G 1p.Ser112Gly

Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.

Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen​.hgvs.org). See Quick Reference for an explanation of nomenclature.

1.

Normal gene product. The ISCA2 NM_194279.3 transcript encodes the 154-amino-acid protein iron-sulfur cluster assembly 2 homolog, mitochondrial (NP_919255.2). It is an A-type iron-sulfur cluster (ISC) protein that has a critical functional domain for iron-sulfur (Fe-S) biogenesis. The protein helps in maturation of mitochondrial iron-sulfur cluster assembly.

Abnormal gene product. Experimental studies indicate that p.Gly77Ser leads to reduced complex II and VI activity in the tested patients' muscle tissues [Alaimo et al 2018, Toldo et al 2018]. Loss of ISCA2 has been shown to diminish mitochondrial membrane potential, the mitochondrial network, basal and maximal respiration, and ATP production and to disrupt the 4Fe-4S cluster machinery [Alaimo et al 2018].

References

Literature Cited

  • Alaimo JT, Besse A, Alston CL, Pang K, Appadurai V, Samanta M, Smpokou P, McFarland R, Taylor RW, Bonnen PE. Loss-of-function mutations in ISCA2 disrupt 4Fe-4S cluster machinery and cause a fatal leukodystrophy with hyperglycinemia and mtDNA depletion. Hum Mutat. 2018;39:537–49. [PMC free article: PMC5839994] [PubMed: 29297947]
  • Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, Hijazi H, Alshammari M, Aldahmesh MA, Salih MA, Faqeih E, Alhashem A, Bashiri FA, Al-Owain M, Kentab AY, Sogaty S, Al Tala S, Temsah MH, Tulbah M, Aljelaify RF, Alshahwan SA, Seidahmed MZ, Alhadid AA, Aldhalaan H, AlQallaf F, Kurdi W, Alfadhel M, Babay Z, Alsogheer M, Kaya N, Al-Hassnan ZN, Abdel-Salam GM, Al-Sannaa N, Al Mutairi F, El Khashab HY, Bohlega S, Jia X, Nguyen HC, Hammami R, Adly N, Mohamed JY, Abdulwahab F, Ibrahim N, Naim EA, Al-Younes B, Meyer BF, Hashem M, Shaheen R, Xiong Y, Abouelhoda M, Aldeeri AA, Monies DM, Alkuraya FS. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep. 2015;10:148–61. [PubMed: 25558065]
  • Alfadhel M, Nashabat M, Alrifai MT, Alshaalan H, Al Mutairi F, Al-Shahrani SA, Plecko B, Almass R, Alsagob M, Almutairi FB, Al-Rumayyan A, Al-Twaijri W, Al-Owain M, Taylor RW, Kaya N. Further delineation of the phenotypic spectrum of ISCA2 defect: a report of ten new cases. Eur J Paediatr Neurol. 2018;22:46–55. [PubMed: 29122497]
  • Al-Hassnan ZN, Al-Dosary M, Alfadhel M, Faqeih EA, Alsagob M, Kenana R, Almass R, Al-Harazi OS, Al-Hindi H, Malibari OI, Almutari FB, Tulbah S, Alhadeq F, Al-Sheddi T, Alamro R, AlAsmari A, Almuntashri M, Alshaalan H, Al-Mohanna FA, Colak D, Kaya N. ISCA2 mutation causes infantile neurodegenerative mitochondrial disorder. J Med Genet. 2015;52:186–94. [PubMed: 25539947]
  • Toldo I, Nosadini M, Boscardin C, Talenti G, Manara R, Lamantea E, Legati A, Ghezzi D, Perilongo G, Sartori S. Neonatal mitochondrial leukoencephalopathy with brain and spinal involvement and high lactate: expanding the phenotype of ISCA2 gene mutations. Metab Brain Dis. 2018 Jan 23; [Epub ahead of print] [PubMed: 29359243]

Chapter Notes

Revision History

  • 22 February 2018 (ma) Review posted live
  • 31 July 2017 (znah) Original submission
Copyright © 1993-2018, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2018 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK481904PMID: 29470032

Views

Tests in GTR by Gene

Related information

  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...